Dr. Ray Takaki Oyakawa, MD

Dr. Oyakawa practices at Sharper Vision Centers in Torrance, California.

Dr. Oyakawa's NPI, 1467541938, was assigned on October 12, 2006. Dr. Oyakawa graduated from UCSF School of Medicine in 1976. Dr. Oyakawa holds California license G44155.

Dr. Oyakawa's primary practice is Sharper Vision Centers, at 20911 Earl St, Torrance, CA 90503-4352. The practice phone is (310) 792-1010.

Dr. Oyakawa's primary practice is Sharper Vision Centers in Torrance, California.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Oyakawa practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Oyakawa's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Oyakawa is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Oyakawa's licenses on file in 4 states: California, North Dakota, Maryland and Florida.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, cold sores or genital herpes, conjunctivitis, dry eye, eyelid inflammation and glaucoma among the conditions Dr. Oyakawa treats.

CMS data shows 1,489 Medicare services from Dr. Oyakawa across 10 procedure codes in 2024, for 273 Medicare patients. Medicare paid $91,647 for them. Every service was in an office.

CMS counts 273 Medicare patients who saw Dr. Oyakawa in 2024. The largest group is 75 to 84, with 117 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 0.99, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Oyakawa's median patient age at 74, with 53% women.

In 2024, Dr. Oyakawa wrote 359 Medicare Part D claims for 86 patients. 45% of them were for generic drugs. CMS names the drug for 277 of them, across 11 drugs with 11 or more claims each, at $42,134 in total drug cost. In 2023, CMS named 325 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 82 out of 100 for Dr. Oyakawa for performance year 2024, reported individually. Dr. Oyakawa accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 32 procedures of cataract surgery by Dr. Oyakawa, more than 54% of the clinicians it reports for that procedure.

Dmand AI links 7 papers to Dr. Oyakawa. The most frequent topics are Visual Acuity, Hemorrhage and Vitreous Body. Dr. Oyakawa has published most often in Am J Ophthalmol. Dr. Oyakawa's most frequent co-author is Thomas A. Rice, MD.

Dmand AI links Dr. Oyakawa to 1 clinical trial. Conditions studied include Macular Edema and Macular Degeneration.

CMS Open Payments shows 21 general payments to Dr. Oyakawa from 8 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 83% of the total. Valeant Pharmaceuticals International paid the most, $690.

Dmand AI lists 2 awards for Dr. Oyakawa, most recently CMS Stage 1 2012 in 2011.

Dr. Oyakawa graduated from UCSF School of Medicine in 1976. Dr. Oyakawa is a member of AAO.

Dr. Oyakawa is in network with 15 carriers, including Aetna, United Healthcare and Elevance. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.